Literature DB >> 22374049

Serum non-high-density lipoprotein cholesterol (non-HDL-C) levels and cardiovascular mortality in chronic hemodialysis patients.

Yoshihisa Echida1, Tetsuya Ogawa, Kuniaki Otsuka, Yoshitaka Ando, Kosaku Nitta.   

Abstract

BACKGROUND: Non-high-density lipoprotein cholesterol (non-HDL-C) has been proposed as a predictor of cardiovascular disease (CVD) in the general population. The aim of this study was to evaluate the utility of non-HDL-C in predicting CV mortality in chronic hemodialysis (HD) patients.
METHODS: We calculated the serum non-HDL-C level of 259 HD patients by subtracting their HDL-C levels from their total cholesterol. Cox proportional hazards models were used to estimate the hazards ratio (HR) for CV mortality and the 95% confidence interval (CI). A receiver-operating characteristic (ROC) analysis was performed to estimate the relationship between sensitivity and specificity of a diagnostic parameter.
RESULTS: There were 44 deaths (17.0%) during the follow-up period, 33 (12.7%) of which were due to CVD. A multivariate Cox analysis with adjustments for age, diabetes, dialysis vintage, systolic blood pressure, serum albumin, and lipid levels showed that non-HDL-C was an independent predictor of CV mortality (HR 1.015, 95% CI 1.004-1.025, p = 0.0083). An ROC analysis showed that the plots of the non-HDL-C levels yielded significant specificity and sensitivity for predicting the risk of CVD mortality in HD patients [area under the curve (AUC) 0.62416; p = 0.0366; cutoff value 111.0 mg/dl]. The Kaplan-Meier survival curves of HD patients showed significant differences in CV mortality according to their tertiles with respect to serum non-HDL-C levels (p = 0.0165).
CONCLUSION: The results of this study suggest that serum non-HDL-C level is a significant CV mortality predictor of chronic HD patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22374049     DOI: 10.1007/s10157-012-0615-5

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  22 in total

1.  Non-high-density lipoprotein cholesterol level as potential risk predictor and therapy target.

Authors:  S M Grundy
Journal:  Arch Intern Med       Date:  2001-06-11

Review 2.  Plasma lipoprotein abnormalities in hemodialysis patients--clinical implications and therapeutic guidelines.

Authors:  Tetsuo Shoji; Yoshiki Nishizawa
Journal:  Ther Apher Dial       Date:  2006-08       Impact factor: 1.762

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  Overview of regular dialysis treatment in Japan (as of 31 December 2008).

Authors:  Shigeru Nakai; Kazuyuki Suzuki; Ikuto Masakane; Atsushi Wada; Noritomo Itami; Satoshi Ogata; Naoki Kimata; Takashi Shigematsu; Toshio Shinoda; Tetsuo Syouji; Masatomo Taniguchi; Kenji Tsuchida; Hidetomo Nakamoto; Shinichi Nishi; Hiroshi Nishi; Seiji Hashimoto; Takeshi Hasegawa; Norio Hanafusa; Takayuki Hamano; Naohiko Fujii; Seiji Marubayashi; Osamu Morita; Kunihiro Yamagata; Kenji Wakai; Yuzo Watanabe; Kunitoshi Iseki; Yoshiharu Tsubakihara
Journal:  Ther Apher Dial       Date:  2010-12       Impact factor: 1.762

Review 5.  Lipid changes and statins in chronic renal insufficiency.

Authors:  Eberhard Ritz; Christoph Wanner
Journal:  J Am Soc Nephrol       Date:  2006-12       Impact factor: 10.121

6.  Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality.

Authors:  Y Cui; R S Blumenthal; J A Flaws; M K Whiteman; P Langenberg; P S Bachorik; T L Bush
Journal:  Arch Intern Med       Date:  2001-06-11

7.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

Authors:  Christoph Wanner; Vera Krane; Winfried März; Manfred Olschewski; Johannes F E Mann; Günther Ruf; Eberhard Ritz
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

8.  The association of lipid-modifying medications with mortality in patients on long-term peritoneal dialysis.

Authors:  Alexander S Goldfarb-Rumyantzev; Arsalan N Habib; Bradley C Baird; Lev L Barenbaum; Alfred K Cheung
Journal:  Am J Kidney Dis       Date:  2007-11       Impact factor: 8.860

9.  Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics.

Authors:  Christoph Wanner; Vera Krane; Winfried März; Manfred Olschewski; Hans-Gernot Asmus; Walter Krämer; Karl-Wilhelm Kühn; Heinrich Kütemeyer; Johannes F E Mann; Günther Ruf; Eberhard Ritz
Journal:  Kidney Blood Press Res       Date:  2004-08-16       Impact factor: 2.687

10.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

View more
  8 in total

1.  High glucose concentrations in peritoneal dialysate are associated with all-cause and cardiovascular disease mortality in continuous ambulatory peritoneal dialysis patients.

Authors:  Yueqiang Wen; Qunying Guo; Xiao Yang; Xianfeng Wu; Shaozhen Feng; Jiaqing Tan; Ricong Xu; Xueqing Yu
Journal:  Perit Dial Int       Date:  2013-12-01       Impact factor: 1.756

2.  Relationship between serum fibroblast growth factor-23 level and mortality in chronic hemodialysis patients.

Authors:  Himiko Sugimoto; Tetsuya Ogawa; Yuko Iwabuchi; Kuniaki Otsuka; Kosaku Nitta
Journal:  Int Urol Nephrol       Date:  2013-01-25       Impact factor: 2.370

3.  What's the Optimal Lipids Level for Dialysis Patients? A Cohort Study from a Chinese Dialysis Center in a University Hospital.

Authors:  Wen-Ling Yang; Xue-Yan Zhu; Ning Zhu; Chun-Yan Su; Qing-Feng Han; Tao Wang; Ai-Hua Zhang
Journal:  PLoS One       Date:  2016-12-16       Impact factor: 3.240

4.  Serum Non-High-Density Lipoprotein Cholesterol and Risk of Cardiovascular Disease in Community Dwellers with Chronic Kidney Disease: the Hisayama Study.

Authors:  Tomoko Usui; Masaharu Nagata; Jun Hata; Naoko Mukai; Yoichiro Hirakawa; Daigo Yoshida; Hiro Kishimoto; Takanari Kitazono; Yutaka Kiyohara; Toshiharu Ninomiya
Journal:  J Atheroscler Thromb       Date:  2016-11-12       Impact factor: 4.928

5.  Inverse Association Between Serum Non-High-Density Lipoprotein Cholesterol Levels and Mortality in Patients Undergoing Incident Hemodialysis.

Authors:  Tae Ik Chang; Elani Streja; Gang Jee Ko; Neda Naderi; Connie M Rhee; Csaba P Kovesdy; Moti L Kashyap; Nosratola D Vaziri; Kamyar Kalantar-Zadeh; Hamid Moradi
Journal:  J Am Heart Assoc       Date:  2018-06-09       Impact factor: 5.501

Review 6.  Inflammation and Cardiovascular Disease Associated With Hemodialysis for End-Stage Renal Disease.

Authors:  Yinghui Wang; Lu Gao
Journal:  Front Pharmacol       Date:  2022-02-10       Impact factor: 5.810

7.  U-Shaped Relationship of Non-HDL Cholesterol With All-Cause and Cardiovascular Mortality in Men Without Statin Therapy.

Authors:  Rui-Xiang Zeng; Jun-Peng Xu; Yong-Jie Kong; Jia-Wei Tan; Li-Heng Guo; Min-Zhou Zhang
Journal:  Front Cardiovasc Med       Date:  2022-07-07

8.  The U-Shaped Association of Non-High-Density Lipoprotein Cholesterol Levels With All-Cause and Cardiovascular Mortality Among Patients With Hypertension.

Authors:  Qi Cheng; Xiao-Cong Liu; Chao-Lei Chen; Yu-Qing Huang; Ying-Qing Feng; Ji-Yan Chen
Journal:  Front Cardiovasc Med       Date:  2021-07-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.